Argenx NV Ownership
| ARGX Stock | USD 596.74 4.92 0.83% |
Shares in Circulation | First Issued 2013-03-31 | Previous Quarter 59.4 M | Current Value 65.8 M | Avarage Shares Outstanding 35.4 M | Quarterly Volatility 16.9 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Argenx |
Argenx Stock Ownership Analysis
About 60.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 0.78. argenx NV ADR had not issued any dividends in recent years. argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Ltd, Universit Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands. Argenx Se is traded on NASDAQ Exchange in the United States. For more info on argenx NV ADR please contact EMBA MBA at 31 10 703 8441 or go to https://www.argenx.com.Argenx Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Argenx NV is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading argenx NV ADR backward and forwards among themselves. Argenx NV's institutional investor refers to the entity that pools money to purchase Argenx NV's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bellevue Group Ag | 2024-09-30 | 632.8 K | Clearbridge Advisors, Llc | 2024-06-30 | 617.5 K | Paradigm Biocapital Advisors Lp | 2024-09-30 | 480.4 K | Wellington Management Company Llp | 2024-06-30 | 426.7 K | Holocene Advisors, Lp | 2024-06-30 | 425.6 K | Sei Investments Co | 2024-06-30 | 381.5 K | Deep Track Capital, Lp | 2024-09-30 | 365 K | Alkeon Capital Management, Llc | 2024-09-30 | 345 K | Pictet Asset Manangement Sa | 2024-06-30 | 308.2 K | T. Rowe Price Associates, Inc. | 2024-06-30 | 5.6 M | Fmr Inc | 2024-09-30 | 4.8 M |
Argenx NV Outstanding Bonds
Argenx NV issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. argenx NV ADR uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Argenx bonds can be classified according to their maturity, which is the date when argenx NV ADR has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| ARES 4125 30 JUN 51 Corp BondUS04018VAA17 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| US040133AA87 Corp BondUS040133AA87 | View | |
| ARES CAPITAL PORATION Corp BondUS04010LBA08 | View | |
| ARES CAPITAL PORATION Corp BondUS04010LBB80 | View | |
| ARCC 32 15 NOV 31 Corp BondUS04010LBC63 | View | |
| ARCC 2875 15 JUN 27 Corp BondUS04010LBD47 | View |
Argenx NV Corporate Filings
6K | 20th of November 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Argenx Stock Analysis
When running Argenx NV's price analysis, check to measure Argenx NV's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Argenx NV is operating at the current time. Most of Argenx NV's value examination focuses on studying past and present price action to predict the probability of Argenx NV's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Argenx NV's price. Additionally, you may evaluate how the addition of Argenx NV to your portfolios can decrease your overall portfolio volatility.